跳至主要内容
临床试验/IRCT20210830052346N1
IRCT20210830052346N1招募中3 期

A comparison study of the effects of Jadenu®?(Deferasirox) film-coated tablets and Exjade®?(Deferasirox) tablets for oral suspension on reducing liver and heart iron overload in patients with Beta-Thalassemia Major and Intermedia

Arak University of Medical Sciences0 个研究点目标入组 66 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
66

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
2 years 至 50 years(—)
性别
All

入选标准

  • Age over 2 years old
  • patients with Beta-Thalassemia Major and Intermedia
  • Serum ferritin above 1000 µg / mL
  • Having informed consent to enter the study

排除标准

  • Having contraindication to Jadenu®?and Exjade®?
  • Patients with GFR ?40 mL / min / 1.73 m^2
  • Patients with stunted growth
  • Patients with High-risk myelodysplastic syndromes (MDS)
  • malignant cancer
  • patients with platelet lower than 50x 10^9/L
  • Patients with prior knowledge of allergy to drugs of the defrazirox group
  • Patients with liver failure
  • Patients with gastrointestinal bleeding
  • Patients with renal failure
  • Using other iron chelators at the same time
  • age over 50 years old

研究者

相似试验